Nyxoah S.A. (NASDAQ:NYXH) Q4 2023 Earnings Call Transcript

So also there we will come with a sub analysis. That’s what you can expect from our data.

Suraj Kalia: Got it. And Olivier, I’ll quickly with my follow-up question and avoid the background noise. So Olivier, do you expect Genio eventually to be used in patients who are unwilling to try CPAP? And also, what has been the experience in Germany? Are they more female gender usage is higher than male just given beard issues? Thank you for taking my questions.

Olivier Taelman: So first of all, we have to follow the current guidelines. And that means that patients need to be refractory of quitting CPAP. So that is one thing. So will we become first line? I think in order to do this; HGNS needs to change those guidelines. But for now it’s clear that patients have to have CPAP before they become eligible for an HGNS treatment. So when it comes to the gender of patients, so also there we still see that the majority of patients are male and not female. And when it comes to the fact what you are alluding [Technical Difficulty] we also there we can confirm that patients who are suffering from modern or severe OSA and offer the Genio solutions are really happy to save, if I can say it like this, so that they can really benefit from our technology and from the bilateral stimulation as it is recommended by their surgeon and physician. So I hope that this is answering your question.

Operator: Thank you. And with that, ladies and gentlemen, we conclude our Q&A and program for today. Thank you all for participating. And you may now disconnect.